JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Journal of Nuclear Medicine Vol. 35 No. 6 1017-1022
© 1994 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meredith, R. F.
Right arrow Articles by LoBuglio, A. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meredith, R. F.
Right arrow Articles by LoBuglio, A. F.

Treatment of Metastatic Prostate Carcinoma with Radiolabeled Antibody CC49

Ruby F. Meredith, Anton J. Bueschen, M.B. Khazaeli, Walter E. Plott, William E. Grizzle, Richard H. Wheeler, Jeffrey Schlom, Charles D. Russell, Tiepu Liu and Albert F. LoBuglio

Departments of Radiation Oncology, Urology, Medicine, Pathology, Division of Nuclear Medicine (Radiology), Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama
Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland

Correspondence: For correspondence or reprints contact: Ruby F. Meredith, MD, PhD, University of Alabama at Birmingham, Comprehensive Cancer Center, L.B. Wallace Tumor Institute—117, Birmingham, AL 35294-3300.

ABSTRACT

A Phase II trial of 75 mCi/m2 131I-anti-TAG-72 high-affinity antibody CC49 was studied in 15 patients with hormone-resistant metastatic prostate cancer. Methods: Patients had adequate renal, liver and hematopoietic function. No previous cytotoxic chemotherapy was allowed and previous radiation was limited to 20% of the active bone marrow. Results: No acute adverse reactions occurred, but all patients had evidence of an immune response to CC49 by 4 wk. Six of 10 symptomatic patients had bone pain relief, but no patients met the radiographic or PSA criteria for objective response. Positive imaging of bone and/or soft-tissue lesions was noted for 13 of the 15 patients. Conclusions: CC49 had a high frequency of tumor localization with evidence of anti-tumor effects (pain relief).

Key Words: prostate carcinoma • radiolabeled antibody




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. Baranowska-Kortylewicz, M. Abe, J. Nearman, and C. A. Enke
Emerging Role of Platelet-Derived Growth Factor Receptor-{beta} Inhibition in Radioimmunotherapy of Experimental Pancreatic Cancer
Clin. Cancer Res., January 1, 2007; 13(1): 299 - 306.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. J. Buchsbaum, M.B. Khazaeli, D. B. Axworthy, J. Schultz, T. R. Chaudhuri, K. R. Zinn, M. Carpenter, and A. F. LoBuglio
Intraperitoneal Pretarget Radioimmunotherapy with CC49 Fusion Protein
Clin. Cancer Res., November 15, 2005; 11(22): 8180 - 8185.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
Y. S. Jhanwar and C. Divgi
Current Status of Therapy of Solid Tumors
J. Nucl. Med., January 1, 2005; 46(1_suppl): 141S - 150S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Y. C. Wong, S. Shibata, L. E. Williams, C. S. Kwok, A. Liu, D. Z. Chu, D. M. Yamauchi, S. Wilczynski, D. N. Ikle, A. M. Wu, et al.
A Phase I Trial of 90Y-Anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy with 5-Fluorouracil in Patients with Metastatic Colorectal Cancer
Clin. Cancer Res., December 1, 2003; 9(16): 5842 - 5852.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. De Pascalis, N. R. Gonzales, E. A. Padlan, P. Schuck, S. K. Batra, J. Schlom, and S. V. S. Kashmiri
In Vitro Affinity Maturation of a Specificity-Determining Region-Grafted Humanized Anticarcinoma Antibody: Isolation and Characterization of Minimally Immunogenic High-Affinity Variants
Clin. Cancer Res., November 15, 2003; 9(15): 5521 - 5531.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. J. DeNardo, G. L. DeNardo, A. Yuan, C. M. Richman, R. T. O'Donnell, P. N. Lara, D. L. Kukis, A. Natarajan, K. R. Lamborn, F. Jacobs, et al.
Enhanced Therapeutic Index of Radioimmunotherapy (RIT) in Prostate Cancer Patients: Comparison of Radiation Dosimetry for 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid (DOTA)-Peptide versus 2IT-DOTA Monoclonal Antibody Linkage for RIT
Clin. Cancer Res., September 1, 2003; 9(10): 3938S - 3944.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Shen, R. F. Meredith, J. Duan, D. J. Macey, M.B. Khazaeli, F. Robert, and A. F. LoBuglio
Improved Prediction of Myelotoxicity Using a Patient-Specific Imaging Dose Estimate for Non-Marrow-Targeting 90Y-Antibody Therapy
J. Nucl. Med., September 1, 2002; 43(9): 1245 - 1253.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. M. Goldenberg
Targeted Therapy of Cancer with Radiolabeled Antibodies
J. Nucl. Med., May 1, 2002; 43(5): 693 - 713.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. T. O'Donnell, S. J. DeNardo, A. Yuan, S. Shen, C. M. Richman, P. N. Lara, I. J. Griffith, D. S. Goldstein, D. L. Kukis, G. S. Martinez, et al.
Radioimmunotherapy with 111In/90Y-2IT-BAD-m170 for Metastatic Prostate Cancer
Clin. Cancer Res., June 1, 2001; 7(6): 1561 - 1568.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. R. McDevitt, E. Barendswaard, D. Ma, L. Lai, M. J. Curcio, G. Sgouros, A. M. Ballangrud, W.-H. Yang, R. D. Finn, V. Pellegrini, et al.
An {{alpha}}-Particle Emitting Antibody ([213Bi]J591) for Radioimmunotherapy of Prostate Cancer
Cancer Res., November 1, 2000; 60(21): 6095 - 6100.
[Abstract] [Full Text]

Home page
 JNMHome page
S. Ruan, J. A. O'Donoghue, S. M. Larson, R. D. Finn, A. Jungbluth, S. Welt, and J. L. Humm
Optimizing the Sequence of Combination Therapy with Radiolabeled Antibodies and Fractionated External Beam
J. Nucl. Med., November 1, 2000; 41(11): 1905 - 1912.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. M. Smith-Jones, S. Vallabahajosula, S. J. Goldsmith, V. Navarro, C. J. Hunter, D. Bastidas, and N. H. Bander
In Vitro Characterization of Radiolabeled Monoclonal Antibodies Specific for the Extracellular Domain of Prostate-specific Membrane Antigen
Cancer Res., September 1, 2000; 60(18): 5237 - 5243.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
M. Tempero, P. Leichner, J. Baranowska-Kortylewicz, K. Harrison, S. Augustine, J. Schlom, J. Anderson, J. Wisecarver, and D. Colcher
High-Dose Therapy with 90Yttrium-labeled Monoclonal Antibody CC49: A Phase I Trial
Clin. Cancer Res., August 1, 2000; 6(8): 3095 - 3102.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
L. H. Pai-Scherf, J. A. Carrasquillo, C. Paik, O. Gansow, M. Whatley, D. Pearson, K. Webber, M. Hamilton, C. Allegra, M. Brechbiel, et al.
Imaging and Phase I Study of 111In- and 90Y-labeled Anti-LewisY Monoclonal Antibody B3
Clin. Cancer Res., May 1, 2000; 6(5): 1720 - 1730.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
M. Tamura, D. E. Milenic, M. Iwahashi, E. Padlan, J. Schlom, and S. V. S. Kashmiri
Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only
J. Immunol., February 1, 2000; 164(3): 1432 - 1441.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1994 by the Society of Nuclear Medicine.